OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster
Terry Nolan, Georgia Deliyannis, Maryanne Griffith, et al.
EBioMedicine (2023) Vol. 98, pp. 104878-104878
Open Access | Times Cited: 11
Terry Nolan, Georgia Deliyannis, Maryanne Griffith, et al.
EBioMedicine (2023) Vol. 98, pp. 104878-104878
Open Access | Times Cited: 11
Showing 11 citing articles:
Advances in the design and delivery of RNA vaccines for infectious diseases
Abhijeet Lokras, Thomas Rønnemoes Bobak, Saahil Baghel, et al.
Advanced Drug Delivery Reviews (2024) Vol. 213, pp. 115419-115419
Open Access | Times Cited: 14
Abhijeet Lokras, Thomas Rønnemoes Bobak, Saahil Baghel, et al.
Advanced Drug Delivery Reviews (2024) Vol. 213, pp. 115419-115419
Open Access | Times Cited: 14
Transformative Approaches in SARS-CoV-2 Management: Vaccines, Therapeutics and Future Direction
Ankita Saha, Shweta Choudhary, Priyanshu Walia, et al.
Virology (2025) Vol. 604, pp. 110394-110394
Closed Access | Times Cited: 1
Ankita Saha, Shweta Choudhary, Priyanshu Walia, et al.
Virology (2025) Vol. 604, pp. 110394-110394
Closed Access | Times Cited: 1
Conversion of vaccines from low to high immunogenicity by antibodies with epitope complementarity
Alexandra R Dvorscek, Craig I. McKenzie, Vera C Stäheli, et al.
Immunity (2024)
Closed Access | Times Cited: 8
Alexandra R Dvorscek, Craig I. McKenzie, Vera C Stäheli, et al.
Immunity (2024)
Closed Access | Times Cited: 8
A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection
Lorena M. Coria, Juan M. Corchado, Agostina Demaría, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Lorena M. Coria, Juan M. Corchado, Agostina Demaría, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Australia’s COVID-19 vaccine journey: progress and future perspectives
James A. Triccas, Megan Steain
Microbiology Australia (2024)
Open Access | Times Cited: 5
James A. Triccas, Megan Steain
Microbiology Australia (2024)
Open Access | Times Cited: 5
Tailored Monoacyl Poly(2-oxazoline)- and Poly(2-oxazine)-Lipids as PEG-Lipid Alternatives for Stabilization and Delivery of mRNA-Lipid Nanoparticles
He Xie, Thomas J. Payne, Asuka Takanashi, et al.
Biomacromolecules (2024) Vol. 25, Iss. 7, pp. 4591-4603
Closed Access | Times Cited: 5
He Xie, Thomas J. Payne, Asuka Takanashi, et al.
Biomacromolecules (2024) Vol. 25, Iss. 7, pp. 4591-4603
Closed Access | Times Cited: 5
Rethinking Optimal Immunogens to Face SARS‐CoV‐2 Evolution Through Vaccination
Julià Blanco, Benjamin Trinité, Joan Puig‐Barberà
Influenza and Other Respiratory Viruses (2025) Vol. 19, Iss. 1
Open Access
Julià Blanco, Benjamin Trinité, Joan Puig‐Barberà
Influenza and Other Respiratory Viruses (2025) Vol. 19, Iss. 1
Open Access
Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial
Gonzalo Pérez Marc, Lorena M. Coria, Ana Ceballos, et al.
Vaccine (2025) Vol. 54, pp. 127045-127045
Open Access
Gonzalo Pérez Marc, Lorena M. Coria, Ana Ceballos, et al.
Vaccine (2025) Vol. 54, pp. 127045-127045
Open Access
The Promise of mRNA Vaccines in Cancer Treatment: Technology, Innovations, Applications, and Future Directions
W.H. Wilson Tang, Qianyi Wu, Anqi Liang, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104772-104772
Closed Access
W.H. Wilson Tang, Qianyi Wu, Anqi Liang, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104772-104772
Closed Access
A lipid nanoparticle-mRNA vaccine provides potent immunogenicity and protection againstMycobacterium tuberculosis
Hannah Lukeman, Hareth Al-Wassiti, Stewart A. Fabb, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Hannah Lukeman, Hareth Al-Wassiti, Stewart A. Fabb, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Immunogenicity and Safety of Gamma, Omicron BA.4/5 and Bivalent SARS-CoV-2 RBD-based Protein Booster Vaccines in Adults Previously Immunized with Different Vaccine Platforms: a Phase II/III, Randomized, Clinical Trial.
Gonzalo Perez-Marc, Lorena M. Coria, Ana Ceballos, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Gonzalo Perez-Marc, Lorena M. Coria, Ana Ceballos, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
mRNA vaccines encoding membrane-anchored receptor-binding domains of SARS-CoV-2 mutants induce strong humoral responses and can overcome immune imprinting
Hareth Al-Wassiti, Stewart A. Fabb, Samantha L. Grimley, et al.
Molecular Therapy — Methods & Clinical Development (2024) Vol. 32, Iss. 4, pp. 101380-101380
Open Access
Hareth Al-Wassiti, Stewart A. Fabb, Samantha L. Grimley, et al.
Molecular Therapy — Methods & Clinical Development (2024) Vol. 32, Iss. 4, pp. 101380-101380
Open Access
